AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The company operates a chain of mid-sized multi-speciality hospitals
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
Subscribe To Our Newsletter & Stay Updated